摘要
目的：观察埃克替尼一线治疗晚期非小细胞肺癌表皮生长因子受体（EGFR）敏感性突变患者的疗效及毒副反应。方法：22例接受盐酸埃克替尼治疗的EGFR敏感性突变的NSCLC患者,口服埃克替尼125 mg,3次/d,持续至疾病进展或不良反应无法耐受,评价近期疗效及毒副反应。结果：22例患者中19外显子缺失突变9例,21外显子L858R点突变13例,客观缓解率59.1%,疾病控制率72.7%,中位无进展生存期7.77个月;主要不良反应为皮疹和腹泻,多为Ⅰ~Ⅱ级。结论：盐酸埃克替尼一线治疗EGFR敏感性突变的NSCLC患者疗效较好,不良反应轻。
Objective： To observe the efficacies and toxicities of icotinib hydrochloride as first-line therapy in advanced non-small-cell lung cancer（ NSCLC） patients associated with sensitive epidermal growth factor receptor（ EGFR） gene mutation.Methods： Twenty-two advanced NSCLC patients with sensitive EGFR mutation received icotinib hydrochloride therapy in dose of 125 mg,three times a day,till disease progression or unacceptable toxicity.Then the efficacies and toxicities were evaluated.Results： In 22 patients,exon 19 deletion was detected in 9 cases,and L858 R mutation at exon 21 in 13. The overall response rate（ ORR） was 59. 1%; the disease control rate（ DCR）,72. 7%; and the median progression-free survival（ PFS）,7. 77 months. Major adverse effects were involved in mild skinrash and diarrhea.Conclusion： Icotinib hydrochloride as first-line therapy shows significant anti-tumor activity in advanced NSCLC patients with sensitive EGFR mutation,and the toxicity is well tolerated and acceptable.
作者
金艺凤
田静
产翠翠
汪向海
焦南林
邢敏
陈兴无
JIN Yifeng TIAN Jing CHAN Cuicui WANG Xianghai JIAO Nanlin XING Min CHEN Xingwu(Department of Respiratory Medicine ,The First Affiliated Hospital of Wannan Medical College, Wuhu 241001, China)
出处
《皖南医学院学报》
CAS
2016年第4期337-340,共4页
Journal of Wannan Medical College
关键词
肺肿瘤
盐酸埃克替尼
EGFR
lung neoplasm
icotinib hydrochloride
epidermal growth factor receptor
